Icon

Doribax - (500MG/VIAL ; 250MG/VIAL :Injectible )

Doripenem SHIONOGI INC
500MG/VIAL ; 250MG/VIAL :Injectible
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
None
None None
Indicated as a single agent for the treatment of complicated urinary tract infections, including pyelonephritis caused by Escherichia coli including cases with concurrent bacteremia, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Acinetobacter baumannii.
Yes
****** ** ******** *** ***** ** **** * **** ** *** ******* *** ****** '***, ******** ** **** *, **** *** ************ ********* ** *&* ** ******** ** *** ******. ****** ***** ***** * **** ** *** ***** ****** ****** '***, ******** ** *** **, **** *** ************ ********* ** ******** ** *** ******. ******* **** ***** ** **** *** ********** ****** '***. ****** * *** * **** ***** ***** ******, ********* *** ****** **** ***** **** ** **** ****** '*** *** **** ************ *********. ********** ** ********* **** *** *** **** *********, *** ********* **** ****** ******* ********* ***** *** ***** ** ********* *** *** *****. ****** ******** ******* ******* ** *** **, **** ** **. ** ******** **** *** ******* ********* **** ****** *** ******* ***** *** ****(*.* ***** ****** ** **** ******)
Doribax Patent 1 Patent 2
****** ******* *******
******* *** ******* *******
********* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** *** \ ** *** **, **** ******* **** ****** **** ********
******* *** ** \ ** *** **, **** ******* **** ****** **** ********
********* ** \ ** *** **, **** ******* **** ****** **** ********
  1. *** **, **** : ****** ******** *&* ***** *** **** ** *** ****** '*** - **** *, ****.
  2. *** **, **** : *&* **** ****** ** ******** ** *** ******.
  3. *** **, **** : ***** ****** * *** ****** '******* - *** **, ****.
  4. *** **, **** : ****** ***** * **** ** *********** *** ***** ****** ****** '*** - *** **, ****.
  5. *** **, **** : *&* (********) **** ****** ** ******** ** *** ******.
  6. *** **, **** : ******* ***** * **** ** *********** *** ****** '*** - *** **, ****.
  7. ***** **, **** : ******** **** ******* ** ******** ** *** ******.
  8. *** *, **** : ********** **** ****** *** ********* ***** *** ***** ** ********* *** *** *****.
  9. *** **, **** : ******** ***** * **** ******* ********* ** ******** ***** ** ** ** ********* ***** **** ** **** ****** '***.
  10. *** **, **** : ******** ***** * **** ******* ****** ** ******** ***** ** ** ** ****** ***** **** ** **** ****** '***.
  11. *** **, **** : ********** **** ********* *** ********* ***** *** ***** ** ********* *** *** *****.
  12. *** *, **** : ********** **** ****** *** ********* ***** *** ***** ** ********* *** *** *****.
  13. *** *, **** : ********** **** ******* *** ********* ***** *** ***** ** ********* *** *** *****.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.